OncoCyte Corp. (OCX): Company Cash Funds

OncoCyte Corporation (OCX) collaborates with oncology centers to implement molecular analysis methods for therapy selection. The cash balance history on the GURU.Markets dynamic chart confirms this status, where the value 0.03 reflects the liquidity metric balance. Growth prospects depend on the expansion of insurance coverage for Determa tests, although the early stage of commercialization and high laboratory maintenance costs constrain operating leverage.
Comprehensive metric breakdowns and analytics for OncoCyte (OCX)

This metric captures the absolute volume of liquid assets, forming a fundamental safety cushion to cover operational liabilities. Investors view this resource as a guarantee of financial stability and the company's ability to grow without emergency borrowing. The dynamics of cash and cash equivalents allow for an accurate calculation of the risk management ratio. For OncoCyte Corporation (OCX), this is critically important when scaling laboratory research and implementing new oncology tests. A sufficient cash reserve ensures the uninterrupted provision of biomarker analysis services.